China’s Growing Impact on ADC Growth & Next-Gen Innovation

Antibody-drug conjugates (ADCs) continue to accelerate worldwide, but China’s footprint in the field is expanding at a remarkable pace. With rapid clinical growth, surging deal activity, and a commanding presence in next-generation modalities, China is shaping the future trajectory of ADC development.

This report explores how China-based developers are influencing traditional, bispecific, and dual-payload ADC landscapes-modalities that now make up more than half of all ADC assets globally. From target preferences to investment trends, the analysis provides a focused overview of where China is driving momentum, and how this compares with global activity.